New Drug(NCE) CDMO Service

Kyongbo started its CDMO business for CKD Pharm and Crystalgenomics’ NCEs (New Chemical Entities) and starting from these experiences, we have now the specialized technology in the new drug studies from the early stage to process development & improvement up to commercialization.

Kyongbo has independently separated facilities capable of manufacturing general APIs, cephalosporin and carbapenem antibiotics, cytotoxic anti-cancer APIs and high potency APIs. The quality control is also separated.

Recently, Kyongbo plays a role as a partner to develop domestic and overseas NCE APIs and through know- how based on the long experiences from R&D, production and quality department, Kyongbo provides the problem solving skills and customer specific CMC relevant documentation required by the government regulatory agencies.

Kyongbo Pharm will continue to contribute to the developing of new drugs both domestic and overseas through working timely and efficiently as a new drug developing partner.